Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Executive Summary

UPJOHN PRESIDENT WILLIAM PARFET CONTINUES FAMILY TRADITION of senior management at the company stretching back four generations to Parfet's greatgrandfather William Erastus Upjohn, the founder of the firm. Parfet, 44, will accede to the presidency on Jan. 1, 1991. Upjohn announced the change and the return of a Parfet to top management in the company's traditional end-of-year changes. Parfet will take over some of the responsibilities from Theodore Cooper, MD, who will continue to act as company CEO and chairman of the board. Until two years ago, when William's father Ray stepped down from active management, the positions of Upjohn Chairman and CEO were always held by a Parfet or a Parfet relative. William and Ray Parfet are both members of the board of the directors and William's brother Donald is an executive vice president in charge of administration. In May, 1990 when Upjohn's As the representative of the current generation, William Parfet's progress through the executive ranks has been watched closely since he joined company in 1973. After working his way up through a variety of executive positions in the finance division, Parfet was appointed vice president and treasurer in 1984, was elected to the board of directors in 1985 and became a member of the Office of the Chairman in 1988. In addition to the top operating title, Parfet is getting direct responsibility for the company's worldwide pharmaceutical organization. The worldwide agricultural division, chemical division, consumer products and finance will also report to him. The Upjohn top team will include two new vice-chairmen: Mark Novitch, MD, formerly Exec VP in charge of of pharmaceutical research, medical affairs, pharmaceutical control and pharmaceutical regulatory affairs; and Ley Smith, formerly Exec VP for worldwide pharmaceuticals will both become vice chairmen. Smith's direct responsibilities remain essentially the same. Novitch is giving up R&D to Parfet and assuming strategy and planning, business development and legal/government relations in addition to pharmaceutical control and pharmaceutical regulatory affairs. The company is forming an office composed of 11 executives called the Corporate Management Office. The group is designed to "provide the company with improved executive communication channels, timeliness in decision-making, and a truly integrated strategic focus across our global operations." Also as of Jan. 1, four new executive vice presidents and two new senior vice presidents will take office: Harold Chappelear, currently senior VP for North American pharmaceutical operations and marketing support will become Exec VP in charge of external affairs; D. R. Parfet moves up to Exec VP for administration; Jerry Mitchell, MD, PhD, will be elevated from senior VP and president Upjohn Labs (research) to Exec VP and president of same; and Gerald A. Welch, currently senior VP and general manager for the agricultural division will become an Exec VP and add responsibilities for consumer products and chemicals divisions. The new senior vice presidents will be secretary and general counsel Kenneth M. Cyrus, and chief financial officer, Robert Salisbury.

You may also be interested in...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts